Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript May 8, 2025Corvus Pharmaceuticals, Inc. reports earnings inline with expectations.
Corvus Pharmaceuticals Inc. (CRVS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 6,943,654 | $22,080,820 | 0.53% | |
| 2. | Samlyn Capital Robert Pohly | 4,065,935 | $12,929,674 | -40% | 0.19% |
| 3. | Adams Street Partners Jeffrey Diehl | 3,275,616 | $10,416,459 | 9.22% | |
| 4. | Point72 Asset Management Steve Cohen | 2,787,631 | $8,864,667 | -8% | 0.02% |
| 5. | Vivo Capital Albert Cha And Frank Kung | 2,234,566 | $7,105,920 | 0.94% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.73 | 20,000 | $34,624.00 | 153,773 | 2024-05-06 | Filing | |
| $1.73 | 577,634 | $999,999.98 | 577,634 | 2024-05-06 | Filing | |
| $2.45 | 10,000 | $24,500.00 | 10,000 | 2023-05-15 | Filing | |
| $0.79 | 20,000 | $15,800.00 | 133,773 | 2022-12-20 | Filing | |
| $0.84 | 4,000 | $3,364.00 | 133,238 | 2022-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.96 | 2,000,000 | $9,928,800.00 | 81,077 | 2021-10-01 | Filing | |
| $5.04 | 3,000,000 | $15,131,100.00 | 2,081,077 | 2021-09-30 | Filing | |
| $6.09 | 1,109,644 | $6,757,731.96 | 6,943,654 | 2021-09-20 | Filing | |
| $6.09 | 1,109,644 | $6,757,731.96 | 6,943,654 | 2021-09-20 | Filing | |
| $5.37 | 741,440 | $3,985,165.86 | 1,389,498 | 2020-07-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,679,479 | $8,520,743 | 0.13% | |
| 2. | 2,494,145 | $7,931,381 | 0% | |
| 3. | 1,581,233 | $5,028,321 | 2.75% | |
| 4. | 1,057,018 | $3,361,317 | 0% | |
| 5. | 951,343 | $3,025,271 | 0% |
News See All
10 Low Risk High Reward Stocks Set to Triple by 2030
The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities.
10 Best Multibagger Penny Stocks to Buy According to Billionaires
Penny stocks always seem like bargains for gaining exposure to some of the fastest-growing segments or spectacles, especially when popular stocks cost hundreds or thousands of dollars.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript March 25, 2025Corvus Pharmaceuticals, Inc. misses on earnings expectations.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2024 Business Update and Financial Results Conference Call.
13 Penny Stocks with Insider Buying in 2024
In this article, we will take a detailed look at the 13 Penny Stocks with Insider Buying in 2024. If you want to skip our detailed analysis and see the top 5 stocks in this list, click 5 Penny Stocks...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript
Operator: Good afternoon ladies and gentlemen and welcome to the Corvus Pharmaceuticals' Business Update and Reports First Quarter 2024 Financial Results Conference Call.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2023 Business Update and Financial Results Conference Call.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to the Corvus Pharmaceuticals Second Quarter 2023 Conference Call. [Operator Instructions].
Billionaire Hedge Funds
